ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Q1 2020 Mylan NV Earnings Call
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that President Rajiv Malik and Chief Financial Officer Ken Parks will present at the BofA Securities Virtual Health Care Conference 2020 on Thursday, May 14, 2020 at 3:40 p.m. ET.
Mylan (MYL) delivered earnings and revenue surprises of 2.27% and -2.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
24/7 Wall St. has put together a preview of Applied Materials, Cisco, Norwegian Cruise Line and some of the other most anticipated quarterly reports due this week.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the m…
Moody's Investors Service ("Moody's") assigned an A1 rating to the new senior unsecured notes being issued by Pfizer Inc. ("Pfizer"). This rating is on review for downgrade, consistent with other senior unsecured ratings of Pfizer. There are no changes to Pfizer's existing ratings including the A1 long term rating (on review for downgrade) and the Prime-1 commercial paper rating (not on review for downgrade).
MYL earnings call for the period ending March 31, 2020.
Pfizer (NYSE: PFE) will look like a much different company within a few months as it spins off Upjohn and merges the unit with Mylan. Bristol Myers Squibb (NYSE: BMY) is still integrating Celgene after acquiring the biotech in November. Both Pfizer and BMS have seen their stocks plunge close to 30% this year then make strong rebounds.
Shares of Gilead Sciences Inc. were down 1.2% in trading on Tuesday after the drugmaker listed on its website five generic drugmakers that will produce remdesivir, its experimental COVID-19 treatment. The non-exclusive voluntary licensing agreements are with Cipla Ltd. , Ferozsons Laboratories Ltd. , Hetero Labs Ltd., Jubilant Life Sciences Ltd. and Mylan , to manufacture remdesivir in 127 countries. The Food and Drug Administration recently granted an emergency authorization to remdesivir in the U.S. as a treatment for severely ill COVID-19 patients; it has also been approved in Japan. Neither nation is part of these manufacturing agreements. China, where the virus was first detected in 2019, also isn't listed. Gilead said the licenses will be considered royalty-free until one of two things happens: the World Health Organization lifts its public health emergency of international concern declaration, or another drug or vaccine is approved. Gilead's stock is up 22.8% year-to-date. The S&P 500 is down 9.3%.
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that Executive Chairman Robert J. Coury and President Rajiv Malik will present at the 2020 RBC Capital Markets' Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 8 a.m. ET.
Shares of Mylan gained 0.1% in premarket trading on Monday after the drugmaker reaffirmed its revenue guidance for the year. Mylan had earnings of $20.8 million, or 4 cents per share, in the first quarter of 2020, after a loss of $25 million, or 5 cents per s…
Top news and what to watch in the markets on Monday, May 11, 2020.
Today, Delaware Enhanced Global Dividend and Income Fund (NYSE: DEX) (the "Fund"), a New York Stock Exchange–listed closed-end fund trading under the symbol "DEX," announced that, effective May 19, 2020, Allan Saustrup Jensen will be appointed as co-manager for the Fund. Mr. Jensen will join Damon J. Andres, Åsa Annerstedt, Wayne A. Anglace, Adam H. Brown, Liu-Er Chen, Craig C. Dembek, Roger A. Early, Chris Gowlland, Jens Hansen, Claus Juul, Nikhil G. Lalvani, Paul A. Matlack, John P. McCarthy, Klaus Petersen, and Babak (Bob) Zenouzi in making day-to-day investment decisions for the Fund.
Drug stockpiling drove Mylan's sales 5% higher in the first quarter. Mylan stock rose despite its mixed report. Sales missed estimates, while adjusted profit narrowly beat expectations.
NEWARK, Calif.--(BUSINESS WIRE)--Revance and Mylan Biosimilar to BOTOX® Program Decision to Extend Beyond April 30, 2020
Mylan (NASDAQ: MYL) announced on Tuesday that it has entered into a global partnership with Gilead Sciences (NASDAQ: GILD) to manufacture and distribute remdesivir in 127 low- and middle-income countries as a treatment for COVID-19. Because of the urgent nature of the pandemic, Gilead has indicated its desire to make remdesivir widely available as quickly as possible, and partnering with Mylan will help it accomplish that goal. The pharmaceutical companies have worked together for 15 years in their efforts to fight other infectious diseases including HIV and hepatitis C. Remdesivir is the 10th drug licensed by Gilead to Mylan.
The global generic and specialty pharmaceuticals company, based in the Netherlands, has seen its stock price in a decline for several years. In the daily bar chart of MYL, below, we can see that prices have roughly gone nowhere in the past 12 months. Trading volume has not shown a pattern and the daily On-Balance-Volume (OBV) line has moved up and down with the price action.
Mylan N.V. (NASDAQ: MYL) today announced, as part of its ongoing efforts to support patients and public health needs during the COVID-19 pandemic, a global collaboration with Gilead Sciences to expand access to the investigational antiviral remdesivir for the potential treatment of COVID-19.
MYL earnings call for the period ending March 31, 2020.
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that Executive Chairman Robert J. Coury and President Rajiv Malik will present at the 2020 RBC Capital Markets' Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 8 a.m. ET.
Mylan (MYL) beats on Q1 earnings but misses on sales.
Mylan N.V. (NASDAQ: MYL) has been working since its founding in 1961 to create access to medicine for patients, and that aspiration has included a strong commitment to long-term thinking, sustainability and making a positive impact. Since 2019 is currently ex…
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mylan gets EU nod for its merger with Upjohn.JNJ does a deal with Emergent for COVID-19.Edwards Lifesciences beats expectations.
The number of global cases of COVID-19 rose above 4.31 million on Wednesday, as Russia counted another 10,000 infections and Brazil and Mexico suffered their deadliest day since the start of the pandemic.
U.S. stock index futures rose on Wednesday, after Wall Street's main indexes fell sharply in the previous session, with markets also awaiting comments from Federal Reserve Chairman Jerome Powell amid recent speculation over negative interest rates. Futures traders began pricing in the possibility of negative rates last week and President Donald Trump piled pressure on the Fed again on Tuesday, as the economy reels from the impact of the coronavirus pandemic. Powell's webcast address is expected to start at 9 a.m. ET (1300 GMT).
COVID-19 and its impact on the U.S. economy will continue to take center stage in the week ahead.
In recent sessions, markets have reversed gains built on optimism that U.S. states could slowly end the lockdowns that have crushed the economy. Meanwhile, one major vaccine player, has said the U.S. would have first preference if and when its candidate succe…
You might say that Mylan (NASDAQ: MYL) is a company in waiting. At some point over the next few months, its merger with Pfizer's Upjohn will close. Mylan will be no more; a new company named Viatris will be created from the merger.
A skeleton reaches up from the ground to clutch at a fantastical winged creature. A hunched figure wearing a face mask drags behind it an entangled mass of stricken faces and lanky limbs. A butterfly flutters out of the mouth of a body laid to rest.
It’s Saturday, May 9, 2020, and National Foodies Day. Remember the immortal words of Dr. Johnson: ” He who does not mind his belly, will hardly mind anything else.” It’s also Brunch for Lunch Day (remember, though, that Anthony Bourdain said to never go out f…
John Paulson’s 13F portfolio value decreased from $4.63B to $2.62B this quarter. Paulson & Company's largest three positions are Bausch Health, SPDR Gold Trust
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.Large-cap pharma names AstraZeneca plc (NYSE: AZN) a…
John's Traditional IRA generated a total income of $1,267.84 for March 2020 compared with a total income of $1,154.75 for March 2019.John's Roth IRA generated a total income of $718.18 for March 2020 compared with a total income of $635.40 for March 2019.A to…
Shares of Mylan were rising Monday after the drug maker swung to a first quarter profit in the quarter as consumers stocked up on drugs during the coronavirus pandemic, but still fell just shy of revenue estimates. Mylan reported a 5% jump in quarterly revenue to $2.62 billion with GAAP net earnings of $20.8 million, compared to a net loss of $25 million a year ago. Mylan reported adjusted earnings of 90 cents per share.
Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three months ended March 31, 2020 and reaffirmed its financial guidance for the full year.
Top Research Reports for Intel, Adobe & AMD
Operation Warp Speed: The COVID-19 vaccine race officially goes into high gear with the announcement of USA’s plan to test the 6-odd top vaccine candidates... The post Trumpdesivir: Operation Warp Speed, “Engage.” appeared first on ValueWalk.
Using a pattern of magnetic microtips and magnetically labeled embryonic stem cells, high‐throughput cell aggregation into embryoid bodies can be achieved. The magnetic pattern allows an on/off magneto‐mechanical stimulation of the stem cells, which impressiv…